Author Archives: Steve Bryson PhD

Trial in England of PKG Smartwatch to Monitor Movement Expanding

A £500,000 ($650,000) investment by the National Health Service of England will expand a clinical trial in that country of the Personal KinetiGraph, or PKG smartwatch, a wrist-worn device that can detect abnormal movements in people with Parkinson’s disease. PKG, developed by Global Kinetics and approved by the U.S. Food…

Azilect as Add-on to Requip May Improve Sleep Quality

Azilect (rasagiline) as an add-on therapy to Requip (ropinrole) improved sleep, reduced the need for sleep medications, and enhanced quality of life in a small group of people with Parkinson’s disease, a study suggested. These findings support more extensive studies to confirm the sleep-related benefits of Azilect,…

ABBV-951, Levodopa as Infusion, Seen as Similar to Intestinal Gel

ABBV-951, a continuous infusion formulation of levodopa/carbidopa, brought comparable levels of levodopa into the bloodstream of healthy volunteers as surgically implanted levodopa-carbidopa intestinal gel (LCIG), a Phase 1 study confirmed. Because the delivery of doses can be tailored to a patient’s needs, this alternative form of delivery — a portable…

PDD Patients Given Anavex 2-73 at High Dose Show Range of Benefits

Anavex 2-73 (blarcamesine), an investigational oral therapy for Parkinson’s disease dementia, led to clinically meaningful improvements within all four MDS-UPDRS assessments for patients treated daily at high dose, according to new data from a completed Phase 2 trial. These benefits, in both motor and non-motor Parkinson’s…

Finger Tapping on Smartphone May Measure Parkinson’s Severity

Finger tapping data from Parkinson’s patients using smartphone screens were linked with disease severity in a large-scale analysis that used standard assessment methods. Given that current Parkinson’s severity measurements are based on clinical observations by trained movement disorder specialists, these findings suggest that approaches such as finger tapping analyses…

Aripiprazole at Low Dose Eases Parkinson’s Psychosis, If Tolerable

A low daily dose of aripiprazole, an antipsychotic therapy, significantly eased hallucinations and delusions in people with Parkinson’s disease and psychosis treated in a small, open-label study. Because one-third of the trial’s participants discontinued treatment due to a worsening of disease symptoms, patients using aripiprazole should be monitored closely for tolerability,…

Ask an expert survey graphic

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums